Alexandra Jansen
Family · Cumming, IANPI 1720469976
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,698 of the $5,128 with a category attached, or 72.1%. 25 manufacturers reported payments, led by Genentech USA, Inc. at 30.0% of the total. 2025 is the largest year on record at $1,714, 2.7 times the $632 reported in 2021. Among family clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 248 payments — averaging $20.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$2K
- Sanofi$997
- AstraZeneca$727
- Sanofi-aventis U.S. LLC$532
- GSK$235
- Takeda Pharmaceuticals U.S.A., Inc.$158
- plus $940 from 19 others
What the payments were for
- Consulting fees$87517%
- Food & beverage$3,69872%
- Education$55511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 46 | $1,540 |
| Sanofi | 89 | $997 |
| AstraZeneca | 25 | $727 |
| Sanofi-aventis U.S. LLC | 6 | $532 |
| GSK | 20 | $235 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $158 |
| Pfizer | 7 | $139 |
| Alk-abello, Inc | 6 | $112 |
| Regeneron Healthcare Solutions, Inc. | 6 | $107 |
| Amgen(2 entities) | 6 | $102 |
| Novartis | 5 | $88 |
| Pharming Healthcare, Inc. | 3 | $58 |
| Boehringer Ingelheim | 3 | $45 |
| Grifols USA, LLC | 2 | $44 |
| Biocryst US Sales Co., LLC | 2 | $37 |
| LEO Pharma Inc. | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Galderma Laboratories, L.p. | 2 | $30 |
| Kaleo, Inc. | 2 | $30 |
| Incyte Corporation | 1 | $18 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| USWM, LLC | 1 | $13 |
| Mylan Specialty L.p. | 1 | $13 |
| Organon | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,128 in reported general payments places this provider in the 95th percentile of 1,268 family providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Spiriva RespimatTiotropium Bromide | 18 | $9,856 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $9,586 |
| Epinephrine | 27 | $5,677 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $2,774 |
| Ipratropium Bromide | 82 | $2,157 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $1,586 |
| Ventolin HfaAlbuterol Sulfate | 17 | $887 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 43 | $873 |
| Azelastine Hcl | 31 | $775 |
| Fluticasone Propionate | 24 | $368 |
| Montelukast Sodium | 58 | $316 |
| Famotidine | 23 | $264 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSpiriva Respimat | $45 | $9,85618 claims |
| GSKTrelegy Ellipta | $235 | $9,58616 claims |
| Hikma Pharmaceuticals USAEpinephrine | $15 | $5,67727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,268 family providers in Iowa.
Other family in Cumming
- Stefanie GaticaAnkeny$354K
- Aubrey MolgaardAmes$238K
- Joan KittenFort Dodge$85K
- Megan FergusonPella$82K
- Rodney ClarkDes Moines$63K
- Jennifer CondonFort Dodge$31K
- Karen HunkeAmes$20K
- Tonia AckermanWest Des Moines$17K
- Chi-Ying SageWaterloo$14K
- Amanda GaldiNorth Liberty$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.